相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The U.S. Patent and Trademark Office granted Patent No. US12636339 to Rousselot for Nextida GC, a novel collagen peptide composition targeting healthy post-meal blood glucose levels. - The patent covers both the production process and use of Nextida GC as a dietary supplement ingredient, offering a non-pharmaceutical option for metabolic support. - International patents have also been secured in Australia, Europe, Japan, and China, with additional applications pending across seven other countries. - The milestone strengthens Darling Ingredients' position in the fast-growing metabolic health supplement market through science-backed, natural collagen-based solutions.
- A new study reveals that specific collagen peptides can significantly reduce post-meal blood glucose spikes in healthy individuals and those with prediabetes. - Participants consuming 5 or 10 grams of Nextida GC experienced an average 42% reduction in blood glucose spike 30 minutes after a meal. - The findings suggest that Nextida GC, developed by Rousselot, offers a potential natural supplement for managing blood sugar levels. - Darling Ingredients is committed to developing collagen-based products with health benefits beyond traditional applications, addressing growing consumer demand.
